United Kingdom-based AstraZeneca has completed a contract to divest its commercial rights to Seroquel (quetiapine fumarate immediate release) and Seroquel XR (quetiapine fumarate extended release) in Europe and Russia to Cheplapharm Arzneimittel GmbH (Cheplapharm), it was reported yesterday.
The deal is valued at USD178m. AstraZeneca is also likely to receive future sales-contingent payments of up to USD61m.
The upfront payment will be reported in the company's financial statements within Other Operating Income & Expense in the fourth quarter of 2019.
Genmab to acquire Merus in USD8bn deal to strengthen oncology pipeline
Wolters Kluwer launches UpToDate Expert AI to deliver trusted GenAI clinical decision support
Abbott announces quarterly common dividend
CVS Health declares unchanged quarterly dividend
ALK partners with GenSci to expand allergy immunotherapy market in China
Curatis secures Swiss distribution deal with Phoenix Labs
Innocan Pharma reports 'positive swing' in operating profitability for first half of 2025
Wolters Kluwer boosts medical research efficiency with Ovid AI summarisation
European Commission approves Gilead's twice-yearly HIV prevention injection Yeytuo
Essa Pharma clarifies Nasdaq due bill trading period for cash distribution
Advanz Pharma and Alvotech secure European approval for aflibercept biosimilar Mynzepli
Heron Therapeutics announces tax benefits preservation plan adoption
Essa Pharma sets ex-dividend date and due bill trading for USD80m capital return
BioDlink's bevacizumab injection secures Colombia and Pakistan marketing authorisation
GSK to receive USD370m and future royalties in CureVac/BioNTech settlement